1Marrelli D,Pedrazzani C,Neff A,et al.Complications after extended (D2) and superextended (D3) lymphadenectomy for gastric cancer:analysis of potential risk factors.Ann Surg Onco1,2007,14:25-33.
2Sakuramoto S,Sasako M,Yamaguehi T,et al.Adjuvant chemotherapy for gastric cancer with S-1,an oral fluoropyrimidine.N Engl J Med,2007,357:1810-1820.
3Spanknebel KA,Brennan MF.Is D2 lymphadenectomy for gastric cancer a staging tool or a therapeutic intervention?[J].Surg Oncol Clin N Am,2002; 11(2):415-430.
4Shimada Y.JGCA (The Japan Gastric Cancer Association).Gastric cancer treatment guidelines[J].Jpn J Clin Oncol,2004; 34(1):58.
5Baba M,Hokita S,Natsugoe S,et al.Paraaortic lymphadenectomy in patients with advanced carcinoma of the upper-third of the stomach[J].Hepatogastroenterology,2000; 47(33):893-896.
6Roukos DH,Kappas AM.Perspectives in the treatment of gastric cancer[J].Nat Clin Pract Oncol,2005; 2(2):98-107.
7Nakajima T.Gastric cancer treatment guidelines in Japan[J].Gastric Cancer,2002; 5(1):1-5.
8Maruyama K,Okabayashi K,Kinoshita T.Progress in gastric cancer surgery in Japan and its limits of radicality[J].World J Surg,1987; 11(4):418-425.
9Moriwaki Y,Kobayashi S,Kunisaki C,et al.Is D2 lymphadenectomy in gastrectomy safe with regard to the skill of the operator?[J].Dig Surg,2001; 18(2):111-117.
10Nitti D,Marchet A,Olivieri M,et al.Lymphadenectomy in patients with gastric cancer.A critical review[J].Suppl Tumori,2003; 2(5):S35-S38.
